Ascendis Wins FDA Approval For Rare Disease Therapy

Finviz2026/03/02 13:03

By:Finviz

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ascendis Pharma A/S (NASDAQ:ASND) shares are up during Monday’s premarket session following the FDA’s approval of Yuviwel (navepegritide; developed as TransCon CNP), the first and only once-weekly treatment for children with achondroplasia.

FDA Approval

The FDA approved Yuviwel, a prodrug designed to increase linear growth in children aged two years and older with achondroplasia, based on data from three randomized clinical trials.

Achondroplasia is a rare genetic disorder causing dwarfism, characterized by short limbs, a normal-sized torso, and a large head.

Ascendis Pharma plans to make Yuviwel available through prescribing physicians in the U.S. during the early part of the second quarter of 2026.

In November, Ascendis Pharma announced that pivotal week 52 results from its ApproaCH Trial of investigational once-weekly TransCon CNP (navepegritide) in children with achondroplasia have been published in JAMA Pediatrics, a journal of the American Medical Association.

The authors report that treatment with TransCon CNP led to significantly higher annualized growth velocity (AGV) at week 52 compared to placebo (primary endpoint), as well as improved lower-limb alignment and body proportionality and positive changes in health-related quality of life, with a safety and tolerability profile similar to placebo.

Additionally, the approval includes a Rare Pediatric Disease Priority Review Voucher, which could expedite future drug applications. This development marks a significant advancement in treatment options for a condition that affects many children, providing a new avenue for growth in Ascendis Pharma’s portfolio.

Technical Analysis

The stock is currently trading 0.42% below its 20-day simple moving average (SMA) and 2.45% above its 100-day SMA, indicating some short-term weakness but longer-term strength. Over the past 12 months, shares have increased significantly and are currently positioned closer to their 52-week highs than lows.

The RSI is at 50.00, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is at 0.15, below its signal line at 0.22, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.

Key Resistance: $242.00
Key Support: $230.00

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $261.21. Recent analyst moves include:

Oppenheimer: Outperform (Raises Target to $262.00) (Feb. 12)
Wedbush: Outperform (Raises Target to $273.00) (Feb. 12)
B of A Securities: Buy (Raises Target to $260.00) (Jan. 30)

ASND Price Action: Ascendis Pharma shares were up 3.21% at $241.00 during premarket trading on Monday, according to Benzinga Pro data.

Photo by Tada Images via Shutterstock

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

1. Markets diverged during the week. Between the October 23 and October 30 closes, BTC fell 4.78%, the Nasdaq 100 declined 1.98%, and gold and silver dropped 2.72% and 8.59%, respectively. The DAX, KOSPI, Nikkei 225 and Hang Seng advanced. We focus on differences in growth prospects, valuation sensitivity and risk exposures rather than applying a single directional view across assets. 2. Market reactions to Alphabet's and Intel's earnings brought returns on AI investment into focus. Attention is shifting from the scale of capital expenditure to revenue realization, margins and free cash flow. Lower interest rates can ease discount-rate pressure, but a sustained valuation recovery still requires support from both operating performance and financing conditions. 3. The November 3 US midterm elections and November 6 employment report are key events in the coming week. We monitor how post-election fiscal and legislative agendas may affect interest rates, the dollar and industry operating conditions. Our execution priorities are to manage leverage and concentration, retain margin and exit-liquidity buffers, and avoid treating a single political outcome as an automatic trading signal. 4. Following Binance's disclosure of a security incident, industry attention to endpoint protection, access segregation and coordinated incident response has increased. Key assets to monitor: BTC, the Nasdaq 100, crude oil and gold, alongside upcoming earnings from AAPL, AMD, PLTR, ARM, ANET and QCOM.

Bitget•2026/11/02 08:28